Clinical trials: Aggressive Behaviour
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab.
- Conditions
- Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma
- Trial name
- NCT03061188
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Aggression
Transcranial Direct Current Stimulation and Antisocial Behavior
The main objective of this study is to investigate the causal relationship between prefrontal cortex activity and antisocial behavior, as well as risk factors for antisocial behavior.
- Trial name
- NCT04204759
- Testing
- Transcranial direct current stimulation
- Where
- Singapore
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Nanyang Technological University
Burkitt Lymphoma, Precursor B-cell Lymphoblastic Leukemia-Lymphoma
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL)…
- Trial name
- NCT01786096
- Testing
- SGN-CD19A
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Seagen Inc.
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Testing the Safety of CB-5339 in Patients With Cancer
This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04372641
- Testing
- p97 Inhibitor CB-5339 Tosylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
- Trial name
- NCT05458297
- Testing
- Zilovertamab vedotin, Nemtabrutinib
- Where
- 109 sites in United States, Brazil and 19 more
- Volunteers
- 189 people
- Sponsor
- Merck Sharp & Dohme LLC
Aggression, Forensic Psychiatric Patients
Hasan Kalyoncu University
Aggression is a serious problem that appears to be common in forensic psychiatric patients. Determining factors related to aggression is important for psychiatric nurses during the treatment, care and rehabilitation of patients.
- Trial name
- HKU (NCT06453070)
- Testing
- No intervention was made
- Where
- Turkey (Türkiye)
- Volunteers
- 103 people
- Sponsor
- Hasan Kalyoncu University
Obstructive Coronary Artery Disease, Coronary Artery Disease
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well known that the reduction of cholesterol levels by statin therapy is associated with significant decreases in plaque burden.
- Trial name
- NCT01837823
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT03483103
- Testing
- lisocabtagene maraleucel
- Where
- 59 sites in United States
- Volunteers
- 74 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Endocrine Tumor
A Research Registry on Aggressive PitNETs
To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours.
- Trial name
- RECAPitNETT (NCT05974696)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Chronic Periodontitis, Aggressive Periodontitis
Estimation of Pentrexin-3 Levels in GCF and Saliva of Patients With Periodontal Disease
Subjects were selected from the outpatient clinic, Department of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Cairo University.
- Trial name
- NCT03128502
- Volunteers
- 40 people
- Sponsor
- Cairo University
Mature B-cell Non-Hodgkin Lymphoma
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the…
- Trial name
- B-NHL (NCT07168980)
- Testing
- Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Children's Cancer Group, China
Peripheral T-cell Lymphomas
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
The primary objectives of this study are to: 1. establish the safety and dose limiting toxicities of combining alemtuzumab with CHOP chemotherapy for patients with newly diagnosed aggressive T-cell lymphomas; and 2.
- Trial name
- ACCAPELA (NCT00453427)
- Testing
- Alemtuzumab (Campath-1H)
- Where
- 5 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Aggression
The Effect of Rapid Transcranial Magnetic Stimulation (rTMS) on Aggression in Forensic Patients
Forensic patients will undergo 30 rTMS treatments, once per day each business day using a 1Hz frequency at the right dorso-lateral pre frontal cortex, located using modified BEAM F3.
- Trial name
- NCT02990442
- Testing
- rTMS
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Lymphoma, Non Hodgkin's Lymphoma
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
We now propose to investigate the combination of CHOP-Rituxan plus PEG-Filgrastim (PEG-filgrastim) and GM-CSF. PEG-Filgrastim would be given in order to allow us to administer the chemotherapy courses every 2 weeks with the…
- Trial name
- CHOP-R (NCT01527422)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
- Where
- Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Fernando Cabanillas
Aggression
Virtual Reality Intervention (VR-GINSO) for Reducing Aggression in Young Offenders
The goal of this clinical trial is to see if a specific intervention program that uses virtual reality (VR) helps young people reduce aggressive behavior more than the same program without VR or their usual treatment.
- Trial name
- VR-GINSO (NCT07484919)
- Testing
- Virtual Reality, Active Control, Treatment as usual
- Where
- Spain
- Volunteers
- 110 people
- Sponsor
- Universidad Francisco de Vitoria
Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on patients with relapsed aggressive (high-risk)…
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT01686165
- Testing
- belinostat, rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Arizona
Video Game Addiction, Gaming Disorder
Community-Based Intervention to Reduce Problematic Video Game Use in First-Year Secondary School Students: A Cluster Randomised Controlled Trial
This cluster randomised controlled trial will evaluate whether a community-based, multicomponent intervention can reduce problematic video game use and gaming disorder among first-year secondary school students in Pontevedra…
- Trial name
- AQJ (NCT07357792)
- Testing
- Community-Based Component, Adolescent Mindfulness Component, Adult Mindfulness Component
- Where
- Spain
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- Fundacin Biomedica Galicia Sur
Aggression, Intellectual Disability
Reducing Aggression Among People With an Intellectual Disability
The study is an randomised controlled trial (RCT) to test whether supplementation of vitamins, minerals and n-3 fatty acids may reduce aggressive behavior in people with intellectual disabilities.
- Trial name
- PSYVB (NCT03212092)
- Testing
- Multivitamin, mineral & n-3 FA
- Where
- 7 sites in Netherlands
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- NCT02139371
- Testing
- Injection of 64Cu-DOTA-AE105
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet